[1]
Rindi, G.; Bordi, C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr. Relat. Cancer, 2003, 10, 427-436.
[2]
Massironi, S.; Sciola, V.; Peracchi, M.; Ciafardini, C.; Spampatti, M.P.; Conte, D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J. Gastroenterol., 2008, 14, 5377-5384.
[3]
Ehehalt, F.; Saeger, H.D.; Schmidt, C.M.; Grutzmann, R. Neuroendocrine tumors of the pancreas. Oncologist, 2009, 14, 456-467.
[4]
Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; Evans, D.B. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26(18), 3063-3072.
[5]
Cuccurullo, V.; Cascini, G.L.; Tamburrini, O.; Mansi, L.; Rotondo, A. Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest. Minerva Endocrinol., 2011, 36(1), 41-52.
[6]
Raman, S.P.; Hruban, R.H.; Cameron, J.L.; Wolfgang, C.L.; Fishman, E.K. Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. AJR Am. J. Roent, 2012, 199(2), 309-318.
[7]
Krenning, E.P.; Kwekkeboom, D.J.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Oei, H.Y. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 1993, 20(8), 716-731.
[8]
Chiti, A.; Briganti, V.; Fanti, S.; Monetti, N.; Masi, R.; Bombardieri, E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q. J. Nucl. Med., 2000, 44(1), 42-49.
[9]
Adams, S.; Baum, R.; Rink, T.; Schumm-Drager, P.M.; Usadel, K.H.; Hor, G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur. J. Nucl. Med., 1998, 25(1), 79-83.
[10]
Ambrosini, V.; Tomassetti, P.; Franchi, R.; Fanti, S. Imaging of NETs with PET radiopharmaceuticals. Q. J. Nucl. Med., 2010, 54(1), 16-23.
[11]
Yang, J.; Kan, Y.; Ge, B.H.; Yuan, L.; Li, C.; Zhao, W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: A meta-analysis. Acta Radiol., 2014, 55(4), 389-398.
[12]
Imperiale, A.; Sebag, F.; Vix, M.; Castinetti, F.; Kessler, L.; Moreau, F. 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur. J. Nucl. Med., 2015, 42(3), 409-418.
[13]
Shih, W.J.; Hirschowitz, E.; Bensadoun, E.; Woodring, J.; Ryo, Yu.; Kraman, S. Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies. Ann. Nucl. Med., 2002, 16(3), 213-219.
[14]
Artiko, V.; Sobic-Saranovic, D.; Pavlovic, S.; Petrovic, M.; Zuvela, M.; Antic, A.; Matic, S.; Odalovic, S.; Petrovic, N.; Milovanovic, A.; Obradovic, V. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC. J. BUON, 2012, 17(3), 537-542.
[15]
Grant, C.S. Insulinoma. Best Pract. Res. Clin. Gastroenterol., 2005, 19(5), 783-798.
[16]
Zhao, Y.P.; Zhan, H.X.; Zhang, T.P.; Cong, L.; Dai, M.H.; Liao, Q. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J. Surg. Oncol., 2011, 103(2), 169-174.
[17]
Guettier, J.M. 1.; Kam, A.; Chang, R.; Skarulis, M.C.; Cochran, C.; Alexander, H.R.; Libutti, S.K.; Pingpank, J.F.; Gorden, P. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: The NIH experience. J. Clin. Endocrinol. Metab., 2009, 94(4), 1074-1080.
[18]
Sotoudehmanesh, R.; Hedayat, A.; Shirazian, N.; Shahraeeni, S.; Ainechi, S.; Zeinali, F. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine, 2007, 31(3), 238-241.
[19]
Wong, M.; Isa, S.H.; Zahiah, M.; Azmi, K.N. Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J. Surg., 2007, 31(3), 586-592.
[20]
Prasad, V.; Sainz-Esteban, A.; Arsenic, R.; Plöckinger, U.; Denecke, T.; Pape, U.F.; Pascher, A.; Kühnen, P.; Pavel, M.; Blankenstein, O. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: An explorative study. Eur. J. Nucl. Med., 2016, 43(9), 1593-1600.
[21]
Hubalewska-Dydejczyk, A.; Kulig, J.; Szybinski, P.; Mikolajczak, R.; Pach, D.; Sowa-Staszczak, A. Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract. Eur. J. Nucl. Med., 2007, 34(10), 1545-1555.
[22]
Hirshberg, B. 1.; Cochran, C.; Skarulis, M.C.; Libutti, S.K.; Alexander, H.R.; Wood, B.J.; Chang, R.; Kleiner, D.E.; Gorden, P. Malignant insulinoma: Spectrum of unusual clinical features. Cancer, 2005, 104(2), 264-272.
[23]
Bourcier, M.E.; Sherrod, A.; DiGuardo, M.; Vinik, A.I. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J. Clin. Endocrinol. Metab., 2009, 94(9), 3157-3162.
[24]
Ong, G.S.; Henley, D.E.; Hurley, D.; Turner, J.H.; Claringbold, P.G.; Fegan, P.G. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur. J. Endocrinol., 2010, 162(5), 1001-1008.
[25]
Gibril, F.; Jensen, R.T. Zollinger-Ellison syndrome revisited, diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr. Gastroenterol. Rep., 2004, 6(6), 454-463.
[26]
Stabile, B.E.; Morrow, D.J.; Passaro, E. Jr. The gastrinoma triangle: operative implications. Am. J. Surg., 1984, 147(1), 25-31.
[27]
Berna, M.J.; Hoffmann, K.M.; Serrano, J.; Gibril, F.; Jensen, R.T. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine , 2006, 85(6), 295-330.
[28]
Pfannenberg, A.C.; Burkart, C.; Krober, S.M.; Eschmann, S.M.; Horger, M.S.; Claussen, C.D. Dual-phase multidetector thin-section CT in detecting duodenal gastrinoma. Abdom. Imaging, 2005, 30(5), 543-547.
[29]
Prinz, R.A. Localization of gastrinomas. Int. J. of pancreatology., 1996, 19(2), 79-91.
[30]
Lew, E.A.; Pisegna, J.R.; Starr, J.A.; Soffer, E.F.; Forsmark, C.; Modlin, I.M.; Walsh, J.H.; Beg, M.; Bochenek, W.; Metz, D.C. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology, 2000, 118(4), 696-704.
[31]
Norton, J.A.; Jensen, R.T. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg. Oncol., 2003, 12(2), 145-151.
[32]
Mekhjian, H.S.; O’Dorisio, T.M. VIPoma syndrome. Semin. Oncol., 1987, 14(3), 282-291.
[33]
Park, S.K.; O’Dorisio, M.S.; O’Dorisio, T.M. Vasoactive intestinal polypeptide-secreting tumours: Biology and therapy. Baillieres Clin. Gastroenterol., 1996, 10(4), 673-696.
[34]
Koch, T.R.; Michener, S.R.; Go, V.L. Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea. Gastroenterology, 1991, 100(1), 99-106.
[35]
Ghaferi, A.A.; Chojnacki, K.A.; Long, W.D.; Cameron, J.L.; Yeo, C.J. Pancreatic VIPomas: Subject review and one institutional experience. J. Gastrointest. Surg., 2008, 12(2), 382-393.
[36]
Cascini, G.L.; Cuccurullo, V.; Tamburrini, O.; Rotondo, A.; Mansi, L. Peptide imaging with somatostatin analogues: more than cancer probes. Curr. Radiopharm., 2013, 6(1), 36-40.
[37]
Kindmark, H.; Sundin, A.; Granberg, D.; Dunder, K.; Skogseid, B.; Janson, E.T. Endocrine pancreatic tumors with glucagon hypersecretion: A retrospective study of 23 cases during 20 years. Med. Oncol., 2007, 24(3), 330-337.
[38]
Wermers, R.A.; Fatourechi, V.; Wynne, A.G.; Kvols, L.K.; Lloyd, R.V. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine , 1996, 75(2), 53-63.
[39]
Maton, P.N.; Gardner, J.D.; Jensen, R.T. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig. Dis. Sci., 1989, 34, 28S-39S.
[40]
Boden, G.; Ryan, I.G.; Eisenschmid, B.L.; Shelmet, J.J.; Owen, O.E. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N. Engl. J. Med., 1986, 314(26), 1686-1689.
[41]
Kuo, S.C.; Gananadha, S.; Scarlett, C.J.; Gill, A.; Smith, R.C. Sporadic pancreatic polypeptide secreting tumors (PPomas) of the pancreas. World J. Surg., 2008, 32(8), 1815-1822.
[42]
Solorzano, C.C.; Lee, J.E.; Pisters, P.W.; Vauthey, J.N.; Ayers, G.D.; Jean, M.E. Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery, 2001, 130(6), 1078-1085.
[43]
Kouvaraki, M.A.; Solorzano, C.C.; Shapiro, S.E.; Yao, J.C.; Perrier, N.D.; Lee, J.E. Surgical treatment of non-functioning pancreatic islet cell tumors. J. Surg. Oncol., 2005, 89(3), 170-185.
[44]
Agarwal, S.K.; Kennedy, P.A.; Scacheri, P.C.; Novotny, E.A.; Hickman, A.B.; Cerrato, A. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm. Metab. Res., 2005, 37(6), 369-374.
[45]
Marx, S.J.; Agarwal, S.K.; Kester, M.B.; Heppner, C.; Kim, Y.S.; Skarulis, M.C. Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog. Horm. Res., 1999, 54, 397-438.
[46]
Agarwal, S.K.; Lee Burns, A.; Sukhodolets, K.E.; Kennedy, P.A.; Obungu, V.H.; Hickman, A.B. Molecular pathology of the MEN1 gene. Ann. N. Y. Acad. Sci., 2004, 1014, 189-198.
[47]
Brandi, M.L.; Gagel, R.F.; Angeli, A.; Bilezikian, J.P.; Beck-Peccoz, P.; Bordi, C.; Conte-Devolx, B.; Falchetti, A.; Gheri, R.G.; Libroia, A.; Lips, C.J.; Lombardi, G.; Mannelli, M.; Pacini, F.; Ponder, B.A.; Raue, F.; Skogseid, B.; Tamburrano, G.; Thakker, R.V.; Thompson, N.W.; Tomassetti, P.; Tonelli, F.; Wells, S.A. Jr., Marx, S.J. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab., 2001, 86(12), 5658-5671.
[48]
Thakker, R. V1.; Newey, P.J.; Walls, G.V.; Bilezikian, J.; Dralle, H.; Ebeling, P.R.; Melmed, S.; Sakurai, A.; Tonelli, F.; Brandi, M.L. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab., 2012, 97(9), 2990-3011.
[49]
Tonelli, F.; Giudici, F.; Fratini, G.; Brandi, M.L. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract., 2011, 17, 33-40.
[50]
Maher, E.R.; Neumann, H.P.; Richard, S. von Hippel-Lindau disease: A clinical and scientific review. Eur. J. Hum. Genet., 2011, 19(6), 617-623.
[51]
Kaelin, W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer, 2002, 2(9), 673-682.
[52]
Shuin, T.; Yamazaki, I.; Tamura, K.; Kamada, M.; Ashida, S. Recent advances in ideas on the molecular pathology and clinical aspects of Von Hippel-Lindau disease. Int. J. Clin. Oncol., 2004, 9(4), 283-287.
[53]
Zhou, C.; Dhall, D.; Nissen, N.N.; Chen, C.R.; Yu, R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas, 2009, 38(8), 941-946.
[54]
Yu, R.; Wawrowsky, K.; Zhou, C. A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol. Nutr., 2011, 58, 258-266.
[55]
Yu, R.; Dhall, D.; Nissen, N.N.; Zhou, C.; Ren, S.G. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One, 2011, 6(8), e23397.
[56]
Stabin, M.G.; Kooij, P.P.; Bakker, W.H.; Inoue, T.; Endo, K.; Coveney, J. Radiation dosimetry for indium-111-pentetreotide. J. Nucl. Med., 1997, 38(12), 1919-1922.
[57]
Cuccurullo, V.; Prisco, M.R.; Di Stasio, G.D.; Mansi, L. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers. Curr. Radiopharm., 2017, 10(2), 74-84.
[58]
Cuccurullo, V.; Di Stasio, G.D.; Prisco, M.R.; Mansi, L. Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs? Indian J. Radiol. Imaging, 2017, 27(4), 509-516.
[59]
Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Radioguided surgery with radiolabeled somatostatin analogs: Not only in GEP-NETs. Nucl. Med. Rev. Cent. East. Eur., 2017, 20(1), 49-56.
[60]
Gabriel, M.; Decristoforo, C.; Donnemiller, E.; Ulmer, H. Watfah, Rychlinski C.; Mather, S.J. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med., 2003, 44(5), 708-716.
[61]
Kunikowska, J.; Lewington, V.; Krolicki, L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of 99mTc-Hynictoc SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT upon clinical management. Clin. Nucl. Med., 2017, 42(12), 905-911.
[62]
Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med., 2007, 48(4), 508-518.
[63]
Cuccurullo, V.; Faggiano, A.; Scialpi, M.; Cascini, G.L.; Piunno, A.; Catalano, O.; Colao, A.; Mansi, L. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? Minerva Endocrinol., 2012, 37, 367-377.
[64]
Madrzak, D.; Mikolajczak, R.; Kaminski, G. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. Nucl. Med. Rev. Cent. East. Eur., 2016, 19(2), 88-92.
[65]
Briganti, V.; Sestini, R.; Orlando, C.; Bernini, G.; La Cava, G.; Tamburini, A.; Raggi, C.C.; Serio, M.; Maggi, M. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin. Cancer Res., 1997, 3, 2385-2391.
[66]
Casini Raggi, C.; Calabrò, A.; Renzi, D.; Briganti, V.; Cianchi, F.; Messerini, L.; Valanzano, R.; Cameron Smith, M.; Cortesini, C.; Tonelli, F.; Serio, M.; Maggi, M.; Orlando, C. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin. Cancer Res., 2002, 8(2), 419-427.
[67]
Ezziddin, S.; Lohmar, J.; Yong-Hing, C.J.; Sabet, A.; Ahmadzadehfar, H.; Kukuk, G. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin. Nucl. Med., 2012, 37(6), e141-e147.
[68]
Bodei, L.; Mueller-Brand, J.; Baum, R.P.; Pavel, M.E.; Hörsch, D.; O’Dorisio, M.S.; O’Dorisio, T.M.; Howe, J.R.; Cremonesi, M.; Kwekkeboom, D.J.; Zaknun, J.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med., 2013, 40(5), 800-816.
[69]
Bakker, W.H.; Breeman, W.A.; Kwekkeboom, D.J.; De Jong, L.C.; Krenning, E.P. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. Q. J. Nucl. Med. Mol. Imaging, 2006, 50(4), 265-271.
[70]
Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Physiopathological premises to Nuclear Medicine Imaging of pancreatic neuroendocrine tumours. Curr. Radiopharm., 2019. In Press
Download PDF Flyer